Message

Including its predecessor, LTT Research Laboratories, Inc., the Company has been a drug discovery venture for more than 30 years, conducting research and development with the aim of “contributing to human health and welfare through the development of groundbreaking new drugs and medical technologies.

The founder, Dr. Yutaka Mizushima (Professor Emeritus, St. Marianna University School of Medicine and former member of the House of Councillors), is a pioneering researcher in DDS (Drug Delivery System), and I (Professor, Sojo University Faculty of Pharmaceutical Sciences and former Director and Professor of Kumamoto University Drug Discovery Research Center), the second generation Chairman of the Company, am a pioneer in DR (Drug Repositioning), We are practicing smart drug discovery (developing drugs quickly and inexpensively) with DDS and DR as our core technologies.

In addition to having a research institute in Shonan health innovation park, our head office is staffed with clinical, manufacturing, intellectual property, and business development specialists. One of our unique characteristics is that we are able to conduct drug development from screening to clinical trials in a single step, despite being a venture company.

Another feature of our business is our strong relationship with China. 

Beijing Tide Pharmaceutical Co., Ltd. a joint venture with China-Japan Friendship Hospital (a Chinese government-affiliated hospital) established in 1995 as a company to manufacture and sell DDS drugs we developed, has grown to become a leading pharmaceutical company in China.

Sino Biopharmaceutical Co., Ltd. (a Hong Kong-listed company, one of China’s largest pharmaceutical groups), which invested in and developed Beijing Tide Pharmaceutical Co., Ltd., became a major shareholder of the Company after evaluating the Company’s technology and human resources, and at the same time, entered into a capital and business alliance with the Company.

In addition to cooperating with both companies to promote drug development in China, we also serve as a liaison between the two companies and act as an intermediary for collaboration (licensing, investment, etc.) with Japanese companies.

Our business model is to develop drugs in collaboration with academia and other companies. For example, we provide academia with our proprietary library of approved drugs and research funds to conduct DR screenings and provide DR consulting services to pharmaceutical companies.

We also introduce companies that are planning to start drug development in China to Sino Biopharmaceuticals co., ltd., and work with them to develop their business in China, as well as intermediating investment from Sino Biopharmaceuticals co., ltd,. We believe that we can contribute to your business and research in these various ways, and we look forward to hearing from you.

We have just partially renewed this website. The purpose of this is to help other companies, academia, shareholders, prospective employers, and many others to better understand our company and to think together about how we can develop together. We look forward to hearing from you and receiving your suggestions.